1009120-03-9

Basic information

• Product Name: (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid
• Synonyms: (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid;METHYL N-METHOXYCARBONYL-2-(OXAN-4-YL)-L-GLYCINATE
• CAS NO: 1009120-03-9
• Molecular Formula: C₉H₁₅NO₅
• Molecular Weight: 217.2191
• Mol File: 1009120-03-9.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 409.9±20.0 °C(Predicted)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• PKA: 4.26±0.10(Predicted)
• CAS DataBase Reference: (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid(1009120-03-9)
• EPA Substance Registry System: (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid(1009120-03-9)

Safety Data

• Hazardous Substances Data: 1009120-03-9(Hazardous Substances Data)

Usage

General Description

(S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid is a chemical compound with the molecular formula C11H17NO5. It is a derivative of an amino acid with a tetrahydropyran group, which is a type of cyclic ether. (S)-2-(Methoxycarbonylamino)-2-(tetrahydro-2H-pyran-4-yl)ethanoic acid can be used as a building block for the synthesis of various pharmaceuticals and organic molecules. It may also have potential applications in medicinal chemistry and drug discovery due to its unique structural features. However, further research is needed to fully understand the potential uses and properties of this compound.

Upstream product

• 1257239-30-7 C₁₀H₁₇NO₅ 
• 368866-32-4 (S)-pyranylglycine methyl ester 
• 894789-28-7 (S)-N-Cbz-pyranyl glycine methyl ester 
• 477584-90-0 methyl 2-(((benzyloxy)carbonyl)amino)-2-(dihydro-2H-pyran-4(3H)-ylidene)acetate 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 811842-25-8 (S)-2-amino-2-(tetrahydro-2 H-pyran-4-yl)acetic acid 
• 79-22-1 methyl chloroformate 

Downstream Products

• 1377604-13-1 methyl (S)-2-((1R,3S,4S)-3-(7-(4-(2-((S)-1-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)pyrroIidin-2-yl)-1H-imidazol-5-yl)phenyl)-1H-naphtho[1,2-d]imidazoI-2-yl)-2-azabicydo[2.2.1]heptan-2-yl)-2-oxo-1-(tetrahydro-2H-pyran-4-yl)ethylcarbamate 
• 1250941-34-4 dimethyl (1,2-ethynediylbis(3,1-phenylene-1H-imidazote-4,2-diyl(2S)-2,1-pyrrolidinediyl((1S)-0.122-oxo-1-(tetrahydro-2H-pyran-4-yl)-2,1-ethanediyl)))biscarbamate 
• 1433280-54-6 [(S)-2-{(2S,4S)-2-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-4-methyl-pyrrolidin-1-yl}-2-oxo-1-(tetrahydropyran-4-yl)-ethyl]-carbamic acid methyl ester 
• 1433280-55-7 [(S)-2-((2S,4S)-4-methyl-2-{4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-pyrrolidin-1-yl)-2-oxo-1-(tetrahydro-pyran-4-yl)-ethyl]-carbamic acid methyl ester 

Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, E, F and L are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.

HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formulas (I) or (II): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.